Ioflupane (123i) Rotop (Ioflupane (123i))

Ioflupane is used in nuclear medicine to assess the dopaminergic system in patients with movement‑disorder conditions.

• Parkinsonian syndromes: provides quantitative imaging of dopamine transporter loss to support diagnosis.
• Parkinson's disease: helps confirm disease presence and stage severity.
• Essential tremor vs Parkinson's disease: assists in differential diagnosis by comparing transporter binding patterns.

• Ioflupane (123I) binds selectively and with high affinity to presynaptic dopamine transporters in the striatum. After intravenous administration, the radiolabelled compound accumulates in dopaminergic neurons, allowing single‑photon emission computed tomography (SPECT) to generate images that reflect the integrity and density of functional dopamine transporters.

Ioflupane is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Headache: transient headache during or after the procedure.
• Injection site pain: localized discomfort at the intravenous site.
• Dizziness: temporary light‑headedness post‑administration.
• Mild flushing: brief skin reddening.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals.
• Severe hypotension: marked drop in blood pressure requiring monitoring.
• Radiation‑related effects: unlikely but possible exposure‑related tissue reactions.
• Cardiac arrhythmia: rare occurrence of irregular heart rhythm.
• Pulmonary embolism: extremely rare clot formation after injection.

When using Ioflupane, clinicians should observe several safety measures.

• Pregnancy: avoid unless clearly needed, as fetal radiation exposure is uncertain.
• Breastfeeding: discontinue nursing for an appropriate interval after administration.
• Renal impairment: consider dose adjustment or increased monitoring.
• Concomitant dopamine‑affecting drugs: assess potential interference with imaging results.
• Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with other substances that influence dopamine transporter binding or radiopharmaceutical distribution.

Major Interactions (Avoid)

• Cocaine or amphetamines: can competitively inhibit transporter binding, compromising image quality.
• Other dopamine transporter ligands: may cause false‑negative or altered scans.
• High‑dose radiopharmaceuticals administered within 24 hours: increase cumulative radiation exposure.

Moderate Interactions (Monitor Closely)

• MAO‑B inhibitors (e.g., selegiline): may modestly affect tracer uptake.
• Selective serotonin reuptake inhibitors (SSRIs): potential mild interference with imaging.
• Antihypertensive agents: monitor blood pressure due to possible additive hypotensive effect.